Developer docs
API playgroundTry for free, no card

Search company profiles

TARIS Biomedical

Full company profile

uuid0000qav

Namestring
TARIS Biomedical
Websiteurl
tarisbiomedical.com
Company typeenum
Private
Founded yearint
2008
Short descriptiontext

TARIS Biomedical was a private Lexington, MA biopharmaceutical company founded in 2008 that developed a proprietary intravesical drug delivery platform for targeted bladder cancer treatment, particularly FGFR-mutated non-muscle-invasive bladder cancer. Acquired by Johnson & Johnson in 2019.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
intravesical drug delivery, bladder cancer therapy, urologic oncology, targeted drug delivery, FGFR inhibitors
Industry2 codes
1Nephrology & Urology Specialty Pharmaceuticals
CodeHLAIACAHPrimaryYes
2Urologic Oncology
CodeHLAKAOABPrimaryNo
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Urologic Oncology Therapeutics
Social media profiles2 records
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

TARIS Biomedical developed a proprietary intravesical drug delivery technology that administers therapeutic agents directly into the bladder for the targeted treatment of bladder cancer. The platform was designed to deliver drugs such as erdafitinib directly to bladder tumors, enabling localized treatment of non-muscle-invasive bladder cancer including tumors carrying FGFR mutations with reduced systemic exposure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 89% complete response rate after 18 months
Product and service1 record
1Intravesical Delivery Technology (TARIS)
CategoryDrug Delivery Technology
Description

A specialized drug delivery technology that administers therapeutic agents directly into the bladder via intravesical delivery, enabling targeted treatment for bladder cancer patients, particularly those with non-muscle-invasive bladder cancer carrying FGFR mutations. The platform forms the foundation for J&J pipeline products including Erda-iDRS and Inlexzo.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Peers10 records
1UroGen Pharma
TypeDirect peer
Description

UroGen develops intravesical therapies for urological cancers, most notably Jelmyto for low-grade upper tract urothelial carcinoma. It is the closest direct competitor in intravesical drug delivery for genitourinary oncology.

2Merck & Co.
TypeBroad incumbent
Description

Merck markets Keytruda for BCG-unresponsive NMIBC and is a dominant incumbent in bladder cancer immunotherapy. It competes with TARIS-derived products for the same non-muscle-invasive bladder cancer patient population.

3Bristol-Myers Squibb
TypeBroad incumbent
Description

BMS markets Opdivo for NMIBC and was an investor in TARIS. It operates in the same bladder cancer treatment space and represents both a competitive threat and a former strategic counterparty.

4Astellas Pharma
TypeBroad incumbent
Description

Astellas is a leader in urologic oncology with Padcev (enfortumab vedotin) for advanced urothelial carcinoma. It targets the same bladder cancer patient population with overlapping mechanisms and commercial reach.

5Pfizer
TypeBroad incumbent
Description

Pfizer has a meaningful bladder cancer franchise including Bavencio (co-marketed with Merck KGaA) and broader oncology infrastructure. It competes for market share in NMIBC and adjacent urothelial indications.

6Incyte Corporation
TypeEmerging player
Description

Incyte developed pemigatinib (Pemazyre), an FGFR inhibitor for cholangiocarcinoma and other FGFR-driven tumors. It is comparable as a developer of selective FGFR-targeted therapies that could be relevant to bladder cancer.

7Taiho Pharmaceutical
TypeEmerging player
Description

Taiho developed futibatinib (Lytgobi), a covalent FGFR inhibitor approved for cholangiocarcinoma. It is a relevant peer in the FGFR inhibitor space that could compete or partner in FGFR-driven bladder cancer.

8Lipella Pharmaceuticals
TypeEmerging player
Description

Lipella is developing intravesical therapies including liposomal formulations for bladder conditions. It is comparable as a small-cap company focused on intravesical drug delivery technology for urological indications.

9Theralase Technologies
TypeEmerging player
Description

Theralase develops intravesical photodynamic therapy for non-muscle-invasive bladder cancer. It represents an emerging alternative non-systemic modality for treating NMIBC patients.

10Roche / Genentech
TypeBroad incumbent
Description

Roche has a broad oncology portfolio and investigational agents in bladder cancer. As a top global oncology player, it represents a broad incumbent competitor and potential strategic counterparty in urologic oncology.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TARIS Biomedical

Urologic Oncology Therapeuticstarisbiomedical.com

TARIS Biomedical was a private Lexington, MA biopharmaceutical company founded in 2008 that developed a proprietary intravesical drug delivery platform for targeted bladder cancer treatment, particularly FGFR-mutated non-muscle-invasive bladder cancer. Acquired by Johnson & Johnson in 2019.

TARIS Biomedical firmographics

Firmographics
Name
TARIS Biomedical
Website
https://tarisbiomedical.com
Company type
Private
Founded year
2008
Operating status
Acquired
Headcount range
11–50 employees
Short description
TARIS Biomedical was a private Lexington, MA biopharmaceutical company founded in 2008 that developed a proprietary intravesical drug delivery platform for targeted bladder cancer treatment, particularly FGFR-mutated non-muscle-invasive bladder cancer. Acquired by Johnson & Johnson in 2019.
Ownership category
akta.pro rank

TARIS Biomedical industry classification

Industry
Product category
Urologic Oncology Therapeutics
NAICS
Medicinal and Botanical Manufacturing (325411), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
akta.pro secondary industry
Urologic Oncology (HLAKAOAB)

Keywords

  • Intravesical drug delivery
  • Bladder cancer therapy
  • Urologic oncology
  • Targeted drug delivery
  • FGFR inhibitors

Where TARIS Biomedical is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Markets served

TARIS Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

TARIS Biomedical product offering

Product offering

Core offering

TARIS Biomedical developed a proprietary intravesical drug delivery technology that administers therapeutic agents directly into the bladder for the targeted treatment of bladder cancer. The platform was designed to deliver drugs such as erdafitinib directly to bladder tumors, enabling localized treatment of non-muscle-invasive bladder cancer including tumors carrying FGFR mutations with reduced systemic exposure.

Differentiator

Problem solved

Functional benefit

Products and services

  • Intravesical Delivery Technology (TARIS) A specialized drug delivery technology that administers therapeutic agents directly into the bladder via intravesical delivery, enabling targeted treatment for bladder cancer patients, particularly those with non-muscle-invasive bladder cancer carrying FGFR mutations. The platform forms the foundation for J&J pipeline products including Erda-iDRS and Inlexzo.

Quantifiable outcome

  • 89% complete response rate after 18 months

Companies that use TARIS Biomedical

Customer profile

Segments1 record

Ideal customer profiles1 record

TARIS Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

TARIS Biomedical partnerships and signals

Strategic signal

Scale indicators1 record

TARIS Biomedical competitors and assessment

Company assessment

Direct peers

  • UroGen Pharma: UroGen develops intravesical therapies for urological cancers, most notably Jelmyto for low-grade upper tract urothelial carcinoma. It is the closest direct competitor in intravesical drug delivery for genitourinary oncology.

Broad incumbents

  • Merck & Co. Merck markets Keytruda for BCG-unresponsive NMIBC and is a dominant incumbent in bladder cancer immunotherapy. It competes with TARIS-derived products for the same non-muscle-invasive bladder cancer patient population.
  • Bristol-Myers Squibb: BMS markets Opdivo for NMIBC and was an investor in TARIS. It operates in the same bladder cancer treatment space and represents both a competitive threat and a former strategic counterparty.
  • Astellas Pharma: Astellas is a leader in urologic oncology with Padcev (enfortumab vedotin) for advanced urothelial carcinoma. It targets the same bladder cancer patient population with overlapping mechanisms and commercial reach.
  • Pfizer: Pfizer has a meaningful bladder cancer franchise including Bavencio (co-marketed with Merck KGaA) and broader oncology infrastructure. It competes for market share in NMIBC and adjacent urothelial indications.
  • Roche / Genentech: Roche has a broad oncology portfolio and investigational agents in bladder cancer. As a top global oncology player, it represents a broad incumbent competitor and potential strategic counterparty in urologic oncology.

Emerging players

  • Incyte Corporation: Incyte developed pemigatinib (Pemazyre), an FGFR inhibitor for cholangiocarcinoma and other FGFR-driven tumors. It is comparable as a developer of selective FGFR-targeted therapies that could be relevant to bladder cancer.
  • Taiho Pharmaceutical: Taiho developed futibatinib (Lytgobi), a covalent FGFR inhibitor approved for cholangiocarcinoma. It is a relevant peer in the FGFR inhibitor space that could compete or partner in FGFR-driven bladder cancer.
  • Lipella Pharmaceuticals: Lipella is developing intravesical therapies including liposomal formulations for bladder conditions. It is comparable as a small-cap company focused on intravesical drug delivery technology for urological indications.
  • Theralase Technologies: Theralase develops intravesical photodynamic therapy for non-muscle-invasive bladder cancer. It represents an emerging alternative non-systemic modality for treating NMIBC patients.

Market position

Customer concentration

TARIS Biomedical social profiles

Digital presence

TARIS Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TARIS Biomedical leadership team

Management profile

Number of profiles

Profiles4 records

TARIS Biomedical funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TARIS Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TARIS Biomedical

What does TARIS Biomedical do?

TARIS Biomedical developed a proprietary intravesical drug delivery technology that administers therapeutic agents directly into the bladder for the targeted treatment of bladder cancer. The platform was designed to deliver drugs such as erdafitinib directly to bladder tumors, enabling localized treatment of non-muscle-invasive bladder cancer including tumors carrying FGFR mutations with reduced systemic exposure.

Is TARIS Biomedical a public or private company?

TARIS Biomedical is a private company. It is classified as corporate owned and is currently acquired.

When was TARIS Biomedical founded?

TARIS Biomedical was founded in 2008. It employs 11 to 50 people.

Where is TARIS Biomedical based?

TARIS Biomedical is headquartered in Lexington, United States, in the North America region.

Who are TARIS Biomedical's main competitors?

UroGen Pharma is listed as a direct peer. Broad incumbents are Merck & Co., Bristol-Myers Squibb, Astellas Pharma, Pfizer and Roche / Genentech. Emerging players are Incyte Corporation, Taiho Pharmaceutical, Lipella Pharmaceuticals and Theralase Technologies.

Does TARIS Biomedical have an API?

No public API is recorded for TARIS Biomedical.

What industry is TARIS Biomedical in?

TARIS Biomedical's product category is Urologic Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAKAOAB, Urologic Oncology. Its NAICS code is 325411 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsJohnson & Johnson Acquires Taris BiomedicalJohnson & Johnson acquired Taris Biomedical, a biotech developing a drug delivery system for bladder diseases including cancer. The deal's financial terms were not disclosed. The company will join Janssen R&D's Oncology Therapeutic Area and continue research in Lexington, Massachusetts.PR NewswireJohnson & Johnson Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder CancerJohnson & Johnson announced the acquisition of TARIS Biomedical LLC, a privately-owned biotechnology company developing novel drug delivery technology for bladder diseases including cancer. TARIS's lead product TAR-200 uses a silicone-based device for continuous medication release into the bladder, and will be integrated into Janssen R&D's Oncology Therapeutic Area while maintaining its research presence in Lexington, Massachusetts. The acquisition aims to address the global unmet need in localized bladder cancer treatment, which affects nearly 550,000 new patients diagnosed worldwide in 2018.PR NewswireResearchers Shed Light on Bladder Cancer Population Not Receiving Curative Intent TherapySwedish researchers analyzed 17 years of longitudinal data from national bladder cancer registries to examine outcomes for nearly 10,000 muscle-invasive bladder cancer patients who did not receive curative-intent therapy, finding that 57 percent did not undergo radical cystectomy despite guideline recommendations. The study revealed a median overall survival of only 8 months, with bladder cancer as the principal cause of death in 63 percent of patients and a median of 2.1 hospitalizations totaling 18.8 hospital days in the first year following diagnosis. TARIS Bio, which funded the research and is developing the TAR-200 system for this underserved patient population, noted that the findings highlight the significant lack of treatment options for patients unfit for invasive procedures.PR NewswireTARIS Announces Presentation of Clinical Data for TAR-302 for Overactive BladderTARIS Bio announced that results of their Phase 1b study of TAR-302 for overactive bladder will be presented at the International Continence Society annual meeting in Gothenburg, Sweden on September 4, 2019. The study demonstrated that TAR-302, which continuously delivers the antimuscarinic agent trospium directly to the bladder with negligible systemic exposure, was safe and showed preliminary efficacy in 11 OAB patients over six weeks. TARIS is currently evaluating TAR-302 for both idiopathic and neurogenic OAB, with a Phase 1 study investigating 12-week continuous use ongoing.PR NewswireTARIS Initiates Clinical Trial of TAR-200 in Combination with Opdivo® (nivolumab) for Patients with Muscle-Invasive Bladder CancerTARIS Bio announced the dosing of the first patient in a Phase 1b clinical trial evaluating TAR-200 in combination with Opdivo (nivolumab) for patients with muscle-invasive bladder cancer, conducted as part of a clinical collaboration with Bristol-Myers Squibb. The open-label trial will enroll up to 25 patients scheduled for radical cystectomy, assessing safety, tolerability, and preliminary efficacy over four 21-day dosing cycles. This combination therapy addresses an unmet need for the majority of MIBC patients who cannot receive standard platinum-based chemotherapy due to frailty concerns.PR NewswireTARIS Announces Positive Results of Phase 1b Trial of TAR-200 in Muscle Invasive Bladder CancerTARIS Bio announced positive safety, tolerability, and preliminary efficacy data from its Phase 1b study of TAR-200 for muscle invasive bladder cancer (MIBC), with 20 patients demonstrating a 50% objective response rate and 40% complete response rate on histopathologic analysis after radical cystectomy. The drug delivery system showed no detectable systemic gemcitabine exposure, favorable tolerability, and no dose-limiting toxicity. The FDA has granted Fast Track designation to TAR-200, and TARIS expects to report topline results from an ongoing Phase 1b study in late 2019.PR NewswireTARIS Bio Initiates New Clinical Study of TAR-302 in Overactive BladderTARIS Bio initiated a new clinical study of TAR-302 for overactive bladder in the U.S., building on earlier results from a Phase 1b trial. The study aims to evaluate safety, tolerability, and efficacy with a treatment duration of 12 weeks, targeting patients refractory to oral medications.PR NewswireTARIS Appoints Tony Kingsley as President and Chief Executive OfficerTARIS Bio appointed Tony Kingsley as its new president and chief executive officer, succeeding founding CEO Purnanand Sarma. This leadership change aims to bolster the biopharmaceutical company's late-stage drug development and commercial expertise as it advances its pipeline for muscle invasive bladder cancer and overactive bladder.FinSMEsTaris Biomedical Raises $32M in Venture Capital FundingTaris Biomedical raised $32M in venture capital led by Flagship Ventures, with participation from Polaris Venture Partners and RA Capital Management. The company will use the funds to advance a new pipeline for bladder diseases, launch clinical trials over the next 12 months, and expand its team.VC News DailyTaris Biomedical Pulls In $32MTaris Biomedical announced it has relaunched with a $32 million financing round led by Flagship Ventures, with participation from Polaris Venture Partners and new investor RA Capital Management. The company will use the proceeds to advance a new pipeline targeting bladder diseases, initially focusing on bladder cancer and overactive bladder, with multiple clinical trials planned over the next 12 months. The financing follows the company's 2014 sale of its lead clinical program for interstitial cystitis to Allergan Inc. in a transaction worth up to $587.5 million.